CORVUS PHARMACEUTICALS INC (CRVS) competitors & alternatives
Health Care · NASDAQ
CORVUS PHARMACEUTICALS INC (CRVS)'s top competitors and alternatives — its most similar public companies — include Gilead Sciences (GILD), Amgen (AMGN), EYEPOINT INC (EYPT), NEKTAR THERAPEUTICS (NKTR), CELLDEX THERAPEUTICS INC (CLDX), Cue Biopharma, Inc. (CUE), JANUX THERAPEUTICS INC (JANX), VIR BIOTECHNOLOGY INC (VIR), XENCOR INC (XNCR), NKARTA INC (NKTX), SANA BIOTECHNOLOGY INC (SANA) and CONTEXT THERAPEUTICS INC (CNTX). These are CORVUS PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top CRVS competitors & alternatives
-
Gilead SciencesGILDHealth Care
A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis,…
$130.34 (as of 2026-07-22) · market cap $163.6B
-
AmgenAMGNHealth Care
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone…
$366.05 (as of 2026-07-22) · market cap $197.7B
-
EYEPOINT INCEYPTHealth Care
EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular…
$12.66 (as of 2026-07-22) · market cap $1.1B
-
NEKTAR THERAPEUTICSNKTRHealth Care
A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
$69.32 (as of 2026-07-22) · market cap $2.4B
-
CELLDEX THERAPEUTICS INCCLDXHealth Care
A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin…
$34.77 (as of 2026-07-22) · market cap $2.7B
-
Cue Biopharma, Inc.CUEHealth Care
Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate…
$34.20 (as of 2026-07-22) · market cap $144M
-
JANUX THERAPEUTICS INCJANXHealth Care
Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of…
$15.62 (as of 2026-07-22) · market cap $953M
-
VIR BIOTECHNOLOGY INCVIRHealth Care
Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking…
$9.35 (as of 2026-07-22) · market cap $1.6B
-
XENCOR INCXNCRHealth Care
Xencor is a clinical-stage biopharmaceutical company leveraging its proprietary XmAb antibody engineering platform to develop innovative multi-specific…
$19.51 (as of 2026-07-22) · market cap $1.4B
-
NKARTA INCNKTXHealth Care
Nkarta is a clinical-stage biotech developing off-the-shelf, engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases through…
$2.41 (as of 2026-07-22) · market cap $172M
-
SANA BIOTECHNOLOGY INCSANAHealth Care
Sana Biotechnology is developing ex vivo and in vivo engineered cell therapy platforms to transform the treatment of diseases like type 1 diabetes, oncology,…
$3.12 (as of 2026-07-22) · market cap $868M
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.61 (as of 2026-07-22) · market cap $56M
Not quite? Describe exactly what you want →
Peers are CORVUS PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: CORVUS PHARMACEUTICALS INC (CRVS).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.